Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

A new study conducted by researchers from the University of Eastern Finland the Karolinska Institutet explored the ways that ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

liraglutide also underpins Novo’s older weight loss drug Saxenda and its insulin-degludec-based diabetes combination therapy Xultophy. While a newer class of GLP-1s based on Novo’s semaglutide ...

Saxenda is a brand-name injectable solution prescribed for long-term weight management in adults and some children. It contains the active ingredient liraglutide. Saxenda is not safe to use during ...

Novo Nordisk (NVO) markets liraglutide under the brand names Victoza, Saxenda and Xultophy. The drug is currently on the FDA's drug shortage list. Compounding pharmacies are allowed to make ...